SAB Biotherapeutics initiated with Buy on risk/reward at Brookline

Brookline last night initiated coverage of SAB Biotherapeutics with a Buy rating and $8 price target. SAB is developing SAB-142 as a potential disease-modifying therapy that can delay the onset and progression of clinical stage 3 type 1 diabetes, the analyst tells investors in a research note. The firm sees a favorable risk/reward as SAB-142 advances through the clinic “as there is a significant unmet need for scalable, efficacious, and safe immunotherapies.”